Amy Lansky
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Amy Lansky has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
Elizabeth DiNenno
U.S. Centers for Disease Control and Prevention, Atlanta, Georgia
4 shared publicationsAmy Drake
Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, USA
3 shared publications- Brian Morrow
National Center for Chronic Disease & Health Promotion, Centers for Disease Control & Prevention
3 shared publications Christopher Johnson
Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
2 shared publicationsCyprian Wejnert
Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
2 shared publicationsJonathan Mermin
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia
2 shared publications
Latest Publications
- Open Access
- 23 August 2024
- Published byĀ ElsevierĀ inĀ AJPM Focus
- Vol.Ā 3 Ā (6) , 100267
Mpox and Vaccine Knowledge, Beliefs, and Sources of Trusted Information Among Gay, Bisexual, and Other Men Who Have Sex With Men in the U.S.
- 23 August 2024
- Published byĀ ElsevierĀ inĀ AJPM Focus
- Vol.Ā 3 Ā (6) , 100267
Open AccessMpox and Vaccine Knowledge, Beliefs, and Sources of Trusted Information Among Gay, Bisexual, and Other Men Who Have Sex With Men in the U.S.
- 17 December 2022
- Published byĀ ElsevierĀ inĀ American Journal of Preventive Medicine
- Vol.Ā 64 Ā (4) , 569-578
Community Guide Methods for Systematic Reviews of Economic Evidence
- 17 December 2022
- Published byĀ ElsevierĀ inĀ American Journal of Preventive Medicine
- Vol.Ā 64 Ā (4) , 569-578
Community Guide Methods for Systematic Reviews of Economic Evidence
- 18 May 2022
- Published byĀ ElsevierĀ inĀ American Journal of Preventive Medicine
- Vol.Ā 62 Ā (6) , e375-e378
Priority Topics for the Community Preventive Services Task Force, 2020ā2025: A Data-Driven, Partner-Informed Approach
- 18 May 2022
- Published byĀ ElsevierĀ inĀ American Journal of Preventive Medicine
- Vol.Ā 62 Ā (6) , e375-e378
Priority Topics for the Community Preventive Services Task Force, 2020ā2025: A Data-Driven, Partner-Informed Approach
- 1 November 2020
- Published byĀ American Public Health AssociationĀ inĀ American Journal of Public Health
- Vol.Ā 110 Ā (11) , 1687-1688
Living Systematic Reviews and Other Approaches for Updating Evidence
American Journal of Public Health (AJPH) from the American Public Health Association (APHA) Living Systematic Reviews and Other Approaches for Updating Evidence, an article from American Journal of Public Health, Vol 110 Issue 11
- 1 November 2020
- Published byĀ American Public Health AssociationĀ inĀ American Journal of Public Health
- Vol.Ā 110 Ā (11) , 1687-1688
Living Systematic Reviews and Other Approaches for Updating Evidence
American Journal of Public Health (AJPH) from the American Public Health Association (APHA) Living Systematic Reviews and Other Approaches for Updating Evidence, an article from American Journal of Public Health, Vol 110 Issue 11
- Open Access
- 27 July 2015
- Published byĀ Public Library of Science (PLoS)Ā inĀ PLOS ONE
- Vol.Ā 10 Ā (7) , e0133543
Estimating the Number of Heterosexual Persons in the United States to Calculate National Rates of HIV Infection
This study estimated the proportions and numbers of heterosexuals in the United States (U.S.) to calculate rates of heterosexually acquired human immunodeficiency virus (HIV) infection. Quantifying the burden of disease can inform effective prevention planning and resource allocation. Heterosexuals were defined as males and females who ever had sex with an opposite-sex partner and excluded those with other HIV risks: persons who ever injected drugs and males who ever had sex with another man. We conducted meta-analysis using data from 3 national probability surveys that measured lifetime (ever) sexual activity and injection drug use among persons aged 15 years and older to estimate the proportion of heterosexuals in the United States population. We then applied the proportion of heterosexual persons to census data to produce population size estimates. National HIV infection rates among heterosexuals were calculated using surveillance data (cases attributable to heterosexual contact) in the numerators and the heterosexual population size estimates in the denominators. Adult and adolescent heterosexuals comprised an estimated 86.7% (95% confidence interval: 84.1%-89.3%) of the U.S. population. The estimate for males was 84.1% (CI: 81.2%-86.9%) and for females was 89.4% (95% CI: 86.9%-91.8%). The HIV diagnosis rate for 2013 was 5.2 per 100,000 heterosexuals and the rate of persons living with diagnosed HIV infection in 2012was 104 per 100,000 heterosexuals aged 13 years or older. Rates of HIV infection were >20 times as high among black heterosexuals compared to white heterosexuals, indicating considerable disparity. Rates among heterosexual men demonstrated higher disparities than overall population rates for men. The best available data must be used to guide decision-making for HIV prevention. HIV rates among heterosexuals in the U.S. are important additions to cost effectiveness and other data used to make critical decisions about resources for prevention of HIV infection.
- 27 July 2015
- Published byĀ Public Library of Science (PLoS)Ā inĀ PLOS ONE
- Vol.Ā 10 Ā (7) , e0133543
Open AccessEstimating the Number of Heterosexual Persons in the United States to Calculate National Rates of HIV Infection
This study estimated the proportions and numbers of heterosexuals in the United States (U.S.) to calculate rates of heterosexually acquired human immunodeficiency virus (HIV) infection. Quantifying the burden of disease can inform effective prevention planning and resource allocation. Heterosexuals were defined as males and females who ever had sex with an opposite-sex partner and excluded those with other HIV risks: persons who ever injected drugs and males who ever had sex with another man. We conducted meta-analysis using data from 3 national probability surveys that measured lifetime (ever) sexual activity and injection drug use among persons aged 15 years and older to estimate the proportion of heterosexuals in the United States population. We then applied the proportion of heterosexual persons to census data to produce population size estimates. National HIV infection rates among heterosexuals were calculated using surveillance data (cases attributable to heterosexual contact) in the numerators and the heterosexual population size estimates in the denominators. Adult and adolescent heterosexuals comprised an estimated 86.7% (95% confidence interval: 84.1%-89.3%) of the U.S. population. The estimate for males was 84.1% (CI: 81.2%-86.9%) and for females was 89.4% (95% CI: 86.9%-91.8%). The HIV diagnosis rate for 2013 was 5.2 per 100,000 heterosexuals and the rate of persons living with diagnosed HIV infection in 2012was 104 per 100,000 heterosexuals aged 13 years or older. Rates of HIV infection were >20 times as high among black heterosexuals compared to white heterosexuals, indicating considerable disparity. Rates among heterosexual men demonstrated higher disparities than overall population rates for men. The best available data must be used to guide decision-making for HIV prevention. HIV rates among heterosexuals in the U.S. are important additions to cost effectiveness and other data used to make critical decisions about resources for prevention of HIV infection.
- 1 November 2014
- Published byĀ ElsevierĀ inĀ Women's Health Issues
- Vol.Ā 24 Ā (6) , 581-583
Declining HIV Incidence Among Women in the United States
- 1 November 2014
- Published byĀ ElsevierĀ inĀ Women's Health Issues
- Vol.Ā 24 Ā (6) , 581-583
Declining HIV Incidence Among Women in the United States
- Open Access
- 19 May 2014
- Published byĀ Public Library of Science (PLoS)Ā inĀ PLOS ONE
- Vol.Ā 9 Ā (5) , e97596
Estimating the Number of Persons Who Inject Drugs in the United States by Meta-Analysis to Calculate National Rates of HIV and Hepatitis C Virus Infections
Injection drug use provides an efficient mechanism for transmitting bloodborne viruses, including human immunodeficiency virus (HIV) and hepatitis C virus (HCV). Effective targeting of resources for prevention of HIV and HCV infection among persons who inject drugs (PWID) is based on knowledge of the population size and disparity in disease burden among PWID. This study estimated the number of PWID in the United States to calculate rates of HIV and HCV infection. We conducted meta-analysis using data from 4 national probability surveys that measured lifetime (3 surveys) or past-year (3 surveys) injection drug use to estimate the proportion of the United States population that has injected drugs. We then applied these proportions to census data to produce population size estimates. To estimate the disease burden among PWID by calculating rates of disease we used lifetime population size estimates of PWID as denominators and estimates of HIV and HCV infection from national HIV surveillance and survey data, respectively, as numerators. We calculated rates of HIV among PWID by gender-, age-, and race/ethnicity. Lifetime PWID comprised 2.6% (95% confidence interval: 1.8%ā3.3%) of the U.S. population aged 13 years or older, representing approximately 6,612,488 PWID (range: 4,583,188ā8,641,788) in 2011. The population estimate of past-year PWID was 0.30% (95% confidence interval: 0.19 %ā0.41%) or 774,434 PWID (range: 494,605ā1,054,263). Among lifetime PWID, the 2011 HIV diagnosis rate was 55 per 100,000 PWID; the rate of persons living with a diagnosis of HIV infection in 2010 was 2,147 per 100,000 PWID; and the 2011 HCV infection rate was 43,126 per 100,000 PWID. Estimates of the number of PWID and disease rates among PWID are important for program planning and addressing health inequities.
- 19 May 2014
- Published byĀ Public Library of Science (PLoS)Ā inĀ PLOS ONE
- Vol.Ā 9 Ā (5) , e97596
Open AccessEstimating the Number of Persons Who Inject Drugs in the United States by Meta-Analysis to Calculate National Rates of HIV and Hepatitis C Virus Infections
Injection drug use provides an efficient mechanism for transmitting bloodborne viruses, including human immunodeficiency virus (HIV) and hepatitis C virus (HCV). Effective targeting of resources for prevention of HIV and HCV infection among persons who inject drugs (PWID) is based on knowledge of the population size and disparity in disease burden among PWID. This study estimated the number of PWID in the United States to calculate rates of HIV and HCV infection. We conducted meta-analysis using data from 4 national probability surveys that measured lifetime (3 surveys) or past-year (3 surveys) injection drug use to estimate the proportion of the United States population that has injected drugs. We then applied these proportions to census data to produce population size estimates. To estimate the disease burden among PWID by calculating rates of disease we used lifetime population size estimates of PWID as denominators and estimates of HIV and HCV infection from national HIV surveillance and survey data, respectively, as numerators. We calculated rates of HIV among PWID by gender-, age-, and race/ethnicity. Lifetime PWID comprised 2.6% (95% confidence interval: 1.8%ā3.3%) of the U.S. population aged 13 years or older, representing approximately 6,612,488 PWID (range: 4,583,188ā8,641,788) in 2011. The population estimate of past-year PWID was 0.30% (95% confidence interval: 0.19 %ā0.41%) or 774,434 PWID (range: 494,605ā1,054,263). Among lifetime PWID, the 2011 HIV diagnosis rate was 55 per 100,000 PWID; the rate of persons living with a diagnosis of HIV infection in 2010 was 2,147 per 100,000 PWID; and the 2011 HCV infection rate was 43,126 per 100,000 PWID. Estimates of the number of PWID and disease rates among PWID are important for program planning and addressing health inequities.
- Open Access
- 7 September 2012
- Published byĀ Bentham Science Publishers Ltd.Ā inĀ The Open AIDS Journal
- Vol.Ā 6 Ā (1) , 77-82
Assessing the Assumptions of Respondent-Driven Sampling in the National HIV Behavioral Surveillance System among Injecting Drug Users
Several assumptions determine whether respondent-driven sampling (RDS) is an appropriate sampling method to use with a particular group, including the population being recruited must know one another as members of the group (i.e., injection drug users [IDUs] must know each other as IDUs) and be networked and that the sample size is small relative to the overall size of the group. To assess these three assumptions, we analyzed city-specific data collected using RDS through the US National HIV Behavioral Surveillance System among IDUs in 23 cities. Overall, 5% of non-seed participants reported that their recruiter was "a stranger." 20 cities with multiple field sites had ā„1 cross-recruitment, a proxy for linked networks. Sample sizes were small in relation to the IDU population size (median = 2.3%; range: 0.6%- 8.0%). Researchers must evaluate whether these three assumptions were met to justify the basis for using RDS to sample specific populations.
- 7 September 2012
- Published byĀ Bentham Science Publishers Ltd.Ā inĀ The Open AIDS Journal
- Vol.Ā 6 Ā (1) , 77-82
Open AccessAssessing the Assumptions of Respondent-Driven Sampling in the National HIV Behavioral Surveillance System among Injecting Drug Users
Several assumptions determine whether respondent-driven sampling (RDS) is an appropriate sampling method to use with a particular group, including the population being recruited must know one another as members of the group (i.e., injection drug users [IDUs] must know each other as IDUs) and be networked and that the sample size is small relative to the overall size of the group. To assess these three assumptions, we analyzed city-specific data collected using RDS through the US National HIV Behavioral Surveillance System among IDUs in 23 cities. Overall, 5% of non-seed participants reported that their recruiter was "a stranger." 20 cities with multiple field sites had ā„1 cross-recruitment, a proxy for linked networks. Sample sizes were small in relation to the IDU population size (median = 2.3%; range: 0.6%- 8.0%). Researchers must evaluate whether these three assumptions were met to justify the basis for using RDS to sample specific populations.
- 15 December 2010
- Published byĀ Wolters Kluwer HealthĀ inĀ JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol.Ā 55 Ā (Supplement) , S64-S68
Epidemiology of HIV in the United States
The United States has a comprehensive system of HIV surveillance, including case reporting and disease staging, estimates of incidence, behavioral, and clinical indicators and monitoring of HIV-related mortality. These data are used to monitor the epidemic and to better design, implement, and evaluate public health programs. We describe HIV-related surveillance systems and review recent data. There are more than 1.1 million people living with HIV in the United States, and approximately 56,000 new HIV infections annually. Risk behavior data show that 47% of men who have sex with men engaged in unprotected anal intercourse in the past year, and 33% of injection drug users had shared syringes. One third (32%) of people diagnosed with HIV in 2008 were diagnosed with AIDS within 12 months, indicating missed opportunities for care and prevention. An estimated 72% of HIV-diagnosed persons received HIV medical care within 4 months of initial diagnosis. Conducting accurate and comprehensive HIV surveillance is critical for measuring progress toward the goals of the 2010 National HIV/AIDS Strategy: reduced HIV incidence, increased access to care, and improvements in health equity.
- 15 December 2010
- Published byĀ Wolters Kluwer HealthĀ inĀ JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol.Ā 55 Ā (Supplement) , S64-S68
Epidemiology of HIV in the United States
The United States has a comprehensive system of HIV surveillance, including case reporting and disease staging, estimates of incidence, behavioral, and clinical indicators and monitoring of HIV-related mortality. These data are used to monitor the epidemic and to better design, implement, and evaluate public health programs. We describe HIV-related surveillance systems and review recent data. There are more than 1.1 million people living with HIV in the United States, and approximately 56,000 new HIV infections annually. Risk behavior data show that 47% of men who have sex with men engaged in unprotected anal intercourse in the past year, and 33% of injection drug users had shared syringes. One third (32%) of people diagnosed with HIV in 2008 were diagnosed with AIDS within 12 months, indicating missed opportunities for care and prevention. An estimated 72% of HIV-diagnosed persons received HIV medical care within 4 months of initial diagnosis. Conducting accurate and comprehensive HIV surveillance is critical for measuring progress toward the goals of the 2010 National HIV/AIDS Strategy: reduced HIV incidence, increased access to care, and improvements in health equity.
- 28 April 2008
- Published byĀ ElsevierĀ inĀ International Journal of Drug Policy
- Vol.Ā 19 Ā (3) , 241-243
Using respondent-driven sampling for behavioural surveillance: Response to Scott
- 28 April 2008
- Published byĀ ElsevierĀ inĀ International Journal of Drug Policy
- Vol.Ā 19 Ā (3) , 241-243
Using respondent-driven sampling for behavioural surveillance: Response to Scott